Search

The article discusses the findings of several studies in relation to rofexocib. The studies concluded that rofexocib appears to be associated with increased risks of adverse cardiovascular events, renal events and arrhythmia. In one paper, several researchers compared the risks of serious CV eventswith COX-2 inhibitors and individual nonsteroidal anti-inflammatory agents. In another paper, researchers aimed to quantify the risks for renal events and arrhythmia events associated with COX-2 inhibitors.